RCS - ValiRx PLC - Inaphaea BioLabs Operational Update

ValiRxAnnouncement

19/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230619:nRSS1172Da&default-theme=true

RNS Number : 1172D  ValiRx PLC  19 June 2023

ValiRx PLC

("ValiRx" or the "Company")

Inaphaea BioLabs Operational Update

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, announces an operational
update from the Company's wholly owned subsidiary, Inaphaea BioLabs Limited
("Inaphaea").

Inaphaea has entered into an agreement with the Virtual CRO services company
OncoBone Limited ("OncoBone") whereby clients of OncoBone can access Inaphaea
services.  OncoBone offers a service to virtual biotech and other biopharma
clients whereby OncoBone designs and commissions pre-clinical work on behalf
of the client.  To conduct the laboratory work, OncoBone engages with a range
of pre-clinical Contract Research Organisations ("CROs") to execute on the
experimental designs that OncoBone has developed.  Inaphaea is now confirmed
as an OncoBone supplier of cell-based assays.

Additionally, Inaphaea is pleased to report that the cell-based assay services
are now listed on scientist.com, a database of CROs that can be used by
biotechnology and pharmaceutical companies to search for scientific
capabilities.

Dr Suzy Dilly, CEO at ValiRx explains "This operational update demonstrates
the progress made by Inaphaea towards generating contract revenues. We're
particularly excited by the prospect of working with OncoBone due to the
innovative nature of their Virtual CRO service."

The Directors of the Company take responsibility for this announcement.

 

For more information, please contact:

 

 ValiRx plc                                                     Tel: +44 (0) 2476 796496

                                                                www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                                          Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 Inaphaea BioLabs Limited                                       www.inaphaea.com (http://www.inaphaea.com/)

 Dr Andrew Carnegie, Head of Strategic Commercial Development   Andrew.Carnegie@inaphaea.com (mailto:Andrew.Carnegie@inaphaea.com)

 V Formation (Public Relations)                                 +44 (0) 115 787 0206

                                                                www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                            lucy@vformation.biz

                                                                sue@vformation.biz
 Cenkos Securities plc (Joint Broker)                           Tel: +44 (0) 20 7397 8900

 Dale Bellis/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)                         Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

About Inaphaea BioLabs

Inaphaea BioLabs is a new pharmaceutical services company, based in Nottingham
(UK), offering cell-based assays specialising in oncology and women's
health.  Our aim is to improve the translation of early drug discovery
projects towards the clinic. Driven by a desire to generate deeper biological
understanding of drug candidates in discovery and preclinical phases of
development, Inaphaea will provide testing services that generate the
necessary data, analysis and insights to aid decision making in translational
drug development.

Spun out from ValiRx PLC, the core team within Inaphaea have a strong
background of preclinical and clinical drug development, and of understanding
both the commercial and scientific needs of the service users from both sides
of the table.

Inaphaea will offer a range of services across all areas of cell-based assays,
including efficacy and selectivity of activity against cancer cells;
mechanistic and binding assays; and measurements of production of cell markers
and hormones.  Inaphaea's services will evolve over time to incorporate new
techniques and technologies with the ambition to improve biological
understanding and translatability of early discovery in drug development.

For further information, visit www.inaphaea.com (http://www.inaphaea.com/)

 About OncoBone

OncoBone offers scientific expertise to pharmaceutical and biotech industry
and their service providers globally. OncoBone representatives have a long
history of working in CRO business and a large global network of high-quality
CRO partners. OncoBone utilizes this extensive experience to guide
pharma/biotech companies in need of CRO services to work with the best fit CRO
partners. OncoBone can assist its pharma/biotech clients in their
preclinical-stage programs through its Virtual CRO concept, where OncoBone
subcontracts the work to its CRO partners and manages the projects internally.

 

 

About Scientist.com

Scientist.com's mission is to empower and connect scientists worldwide. The
company's digital research platform combines a custom-built, cloud native
technology stack with white-glove customer and scientific support to enable
scientists to run more innovative experiments in less time and at lower cost.
Scientist.com leverages internally developed machine learning models to
provide actionable insights that improve operational efficiency and effective
research management. Scientist.com connects the world's top pharmaceutical
companies, biotechnology companies and the US National Institutes of Health
(NIH) to the world's largest network of scientific suppliers.

Visit scientist.com
(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.scientist.com%2F&esheet=53398098&newsitemid=20230511005180&lan=en-US&anchor=scientist.com&index=1&md5=c576a63247f1c7808676d5123889b975)
to learn more.

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFVLLFXQLBBBX